Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3200-3208

  Brack, Simon S ^a   Silacci, Michela ^a   Birchler, Manfred ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; ISOPROTEIN; RADIOACTIVE IODINE; RECOMBINANT ANTIBODY; TENASCIN;

ADULT; AMINO ACID SEQUENCE; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE REPAIR; WOUND HEALING; XENOGRAFT;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; BRAIN NEOPLASMS; EXTRACELLULAR MATRIX; GLIOBLASTOMA; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, NUDE; PROTEIN ISOFORMS; SKIN NEOPLASMS; TENASCIN; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33744811140     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2804     Document Type: Article

References (50)

1. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003; 30:1-5.
2. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
4. Weiner LM, Carter P.Tunable antibodies. Nat Biotechnol 2005;23:556-7.
5. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
6. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
7. van DerVeen AH, ten HagenTL, de Wilt JH, van Ijken MG, Eggermont AM. An overview on the use of TNF-α: our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res 2000;20:3467-74.
8. Brack SS, Dinkelborg LM, Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging 2004;31:1327-41.
9. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998: 273:21769-76.
10. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-42.
11. Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-8.
12. Kaczmarek J, Castellani P, Nicolo G, et al. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994;59:11-6.
13. Tarli L, Balza E, Viti F, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999; 94:192-8.
14. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
15. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-65.
16. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy. Int J Cancer 2005; 116:304-13.
17. Halin C, Gafner V, Villani ME, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor 0. Cancer Res 2003;63:3202-10.
18. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20: 264-9.
19. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61:711-6.
20. Birchler M,Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999;17:984-8.
21. Fabbrini M.Trachsel E, Soldani P, et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006;118:1805-13.
22. Heinis C, Alessi P, Neri D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry 2004;43: 6293-303.
23. Borsi L, Balza E, Bestagno WI, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
24. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053-63s.
25. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005;9:491-500.
26. Borsi L, Carnemolla B, Nicolo G, et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues, Int J Cancer 1992; 52:688-92.
27. Murphy-Ullrich JE, Lightner VA, Aukhil I, et al. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991;115:1127-36.
28. Hindermann W, Berndt A, Borsi L, et al. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999;189:475-80.
29. Kusagawa H, Onoda K, Namikawa S, et al. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 1998;77:98-102.
30. Katenkamp K, Berndt A, Hindermann W, et al. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004;203:771-9.
31. Hauptmann S, Zardi L, Siri A, et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest 1995; 73:172-82.
32. Carnemolla B, Castellani P, Ponassi M, et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999;154:1345-52.
33. Castellani P, Dorcaratto A, Siri A, Zardi L, Viale GL. Tenascin distribution in human brain tumours. Acta Neurochir (Wien) 1995;136:44-50.
34. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
35. 131I radio-conjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I and II study. Acta Oncol 1999;38:351-9.
36. 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004;104:642-8.
37. Paganelli G, Magnani P, Zito F, et al. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med 1994;21: 314-21.
38. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26: 348-57.
39. Petronzelli F, Pelliccia A, Anastasi AM, et al. Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 2005;11: 7137-45s.
40. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-55.
41. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326: 480-505.
42. Scheuermann J, Viti F, Neri D. Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments. J Immunol Methods 2003;276:129-34.
43. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992; 227:776-98.
44. Williams SC, Frippiat JP, Tomlinson IM, et al. Sequence and evolution of the human germline V λ repertoire. J Mol Biol 1996;264:220-32.
45. Hoogenboom HR, Griffiths AD, Johnson KS, et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991;19: 4133-7.
46. Silacci M, Brack S, Schirru G, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005; 5:2340-50.
47. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002;62: 3289-97.
48. Natali PG, Nicotra MR, Bartolazzi A, et al. Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer 1990; 46:586-90.
49. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CHS) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
50. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (CT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-21.